KRRO VS IMNM Stock Comparison

PerformanceEarningsVolatilityTechnicalsProfit
PerformanceEarningsVolatilityTechnicalsProfit

Performance

KRRO
100/100

KRRO returned 192.66% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

IMNM
100/100

IMNM returned 93.25% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Earnings

KRRO
100/100

KRRO has missed earnings 0 times in the last 20 quarters.

IMNM
10/100

IMNM has missed earnings 8 times in the last 20 quarters.

Volatility

KRRO
100/100

KRRO has had a higher than average amount of volatility over the last 12 months giving it a score of 100 of 100.

IMNM
53/100

IMNM has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Technicals

KRRO

"Technicals" not found for KRRO

IMNM
36/100

IMNM receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

Profit

KRRO

"Profit" not found for KRRO

IMNM
10/100

Out of the last 17 quarters, IMNM has had 0 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

Korro Bio, Inc. Common Stock Summary

Nasdaq / KRRO
Healthcare
Biotechnology
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Immunome, Inc. Summary

Nasdaq / IMNM
Healthcare
Biotechnology
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.